Cannabis Science, Inc. has entered into an expanded five-year, $1.8 million Research Collaboration Agreement (RCA) with Dana Farber Cancer Institute, Inc., encompassing operating procedures and related communication activities. The work will be focused on essentially the same clinical targets with expanded work parameters based on current laboratory success. The CBIS/Dana-Farber relationship will leverage the collective experience and expertise of both organizations to jointly develop cannabinoid-based medications and associated delivery technologies for the treatment of cancers, and potentially other indications.